OA: Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, November 12, 2016

OA: Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer



open access: Gynecologic Oncology Reports
 

1.1. Case description

A 59 year old patient was discussed at the gynaecologic oncology multi-disciplinary meeting having presented with abdominal distension with radiological features of an ovarian malignancy. A CT scan demonstrated a complex 16 cm × 13 cm mass arising in the pelvis from the right ovary. Her baseline serum tumour marker ca125 was 34 U/ml She had no medical history of note and was previously fit and well. Her ECOG performance status was 1. There was no family history of malignancy.....

Highlights

  • Case describes a response to sunitinib in clear cell ovarian cancer.
  • Discussion of unique molecular characteristics of clear cell ovarian cancers
  • Practical points regarding dosing and toxicity when using sunitinib discussed


0 comments :

Post a Comment

Your comments?